COMPETING RISKS OF DEATH IN OLDER ADULTS WITH ADVANCED NON-SMALL CELL LUNG CANCER RECEIVING PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) INHIBITORS

被引：0
|
作者：
Kim, Y. [1 ]
Suh, H. S. [2 ]
Park, C. [1 ]
机构：
[1] Univ Texas Austin, Austin, TX USA
[2] Kyung Hee Univ, Coll Pharm, Seoul, South Korea
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO126
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [1] Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis
    Liang, Jiaqi
    Li, Ming
    Sui, Qihai
    Hu, Zhengyang
    Bian, Yunyi
    Huang, Yiwei
    Zhan, Cheng
    Jiang, Wei
    Wang, Qun
    Tan, Lijie
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (04) : 1302 - +
  • [2] Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment
    Li, Feng
    Liao, Binchi
    Wang, Ting
    Qi, Tingting
    Wang, Yixin
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [3] Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer
    Sun, Yuxin
    Shao, Chi
    Li, Shan
    Xu, Yan
    Xu, Kai
    Zhang, Ying
    Huang, Hui
    Wang, Mengzhao
    Xu, Zuojun
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 (06) : 299 - 304
  • [4] Outcomes in Patients with Interstitial Lung Disease Receiving Programmed Cell Death Protein 1 (PD-1) Inhibitors
    Dobre, I.
    Frank, A. J.
    D'Silva, K. M.
    Okin, D.
    Sharma, A.
    Montesi, S. B.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [5] Safety and clinical efficacy of programmed cell death 1 antibodies (PD-1 Ab) in patients with advanced non-small cell lung cancer (NSCLC).
    Ksienski, Doran
    Wai, Elaine
    Croteau, Nicole
    Lesperance, Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (30)
  • [6] Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer
    Jove, Maria
    Vilarino, Noelia
    Nadal, Ernest
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S364 - S368
  • [7] Efficacy of PD-1 Inhibitors in Older Non-small Cell Lung Cancer Patients
    Nakamura, Yukiko
    Miyazaki, Kazuhito
    Aiko, Naoto
    Misumi, Yuki
    Agemi, Yoko
    Taniguchi, Yuri
    Ishi, Mari
    Shimokawa, Tsuneo
    Okamoto, Hiroaki
    Yamanaka, Takeharu
    ANTICANCER RESEARCH, 2020, 40 (02) : 923 - 928
  • [8] Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer
    Khunger, Monica
    Rakshit, Sagar
    Pasupuleti, Vinay
    Hernandez, Adrian V.
    Mazzone, Peter
    Stevenson, James
    Pennell, Nathan A.
    Velcheti, Vamsidhar
    CHEST, 2017, 152 (02) : 271 - 281
  • [9] Programmed cell death protein 1 (PD-1) in infection
    Leth, Steffen
    Jensen-Fangel, Soren
    APMIS, 2020, 128 (02) : 177 - 187
  • [10] SYSTEMATIC REVIEW OF EFFICACY OF PROGRAMMED DEATH (PD)-1 AND PD-LIGAND-1 INHIBITORS IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
    Lingohr-Smith, M.
    Deitelzweig, C.
    Lin, G.
    Lin, J.
    VALUE IN HEALTH, 2020, 23 : S426 - S426
12345